Disease Control Priorities, Third Edition (Volume 6) PDF Download

Author: King K. Holmes
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027

View

Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Author: Dorothee Heemskerk
Publisher: Springer
ISBN: 3319191322
Category : Medical
Languages : en
Pages : 71

View

Book Description
This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases.

Author: Stefan H. E. Kaufmann
Publisher: Wiley-Blackwell
ISBN: 9783527316830
Category : Science
Languages : en
Pages : 1350

View

Book Description
Coinciding with the first TB therapies to enter clinical trials in 60 years, this is the most comprehensive account of the latest developments in clinical, therapeutic and basic research into the disease, presented by the most prolific of all researchers in the field. Divided into three clearly structured volumes, the first deals with molecular biology and biochemistry of the pathogen, including genetics and genomics, as well as drug design. The second volume covers cell biology, immunology and vaccine development, while the third is devoted to epidemiology and clinical approaches, including drug resistance, veterinary aspects and clinical field trials. With one new infection worldwide every second, this is an essential reference for bacteriologists, immunologists, pathologists and pathophysiologists, molecular and cell biologists, as well as those working in the pharmaceutical industry.

Author:
Publisher:
ISBN:
Category : Chest
Languages : en
Pages : 612

View

Book Description

Author: Peter D. O. Davies
Publisher: CRC Press
ISBN: 0429586493
Category : Medical
Languages : en
Pages : 482

View

Book Description
Completely updated and revised, Clinical Tuberculosis continues to provide the TB practitioner-whether in public health, laboratory science or clinical practice-with a synoptic and definitive account of the latest methods of diagnosis, treatment and control of this challenging and debilitating disease.New in the Fifth Edition:Gamma interferon-based

Author: Anthony M. Lowell
Publisher:
ISBN:
Category : Tuberculosis
Languages : en
Pages : 330

View

Book Description

Author: Onn Min Kon
Publisher: Springer Nature
ISBN: 3030755096
Category : Medical
Languages : en
Pages : 378

View

Book Description
This book is targeted at ensuring frontline clinical staff including seniors, trainees and specialist nurses can easily reference the optimum investigation and management of potential TB cases. This will mirror the annual London Advanced TB course which aims to equip all of the team delivering care to have a working knowledge of the entire spectrum of the real life aspects of TB management ranging from investigation of active TB to latent screening in pre biologic therapy. It includes an update of MDR TB management and also the approaches needed to ensure the entire medico-social spectrum of TB care is addressed.

Author:
Publisher:
ISBN:
Category : Chest
Languages : en
Pages : 446

View

Book Description

Author: World Health Organization
Publisher:
ISBN: 9789241548748
Category : Medical
Languages : en
Pages : 0

View

Book Description
It is estimated that one third of the world's population is infected with Mycobacterium tuberculosis (the bacterium that causes tuberculosis (TB)), and that each year, about 9 million people develop TB, of whom about 2 million die. Of the 9 million annual TB cases, about 1 million (11%) occur in children (under 15 years of age). Of these childhood cases, 75% occur annually in 22 high-burden countries that together account for 80% of the world's estimated incident cases. In countries worldwide, the reported percentage of all TB cases occurring in children varies from 3% to more than 25%. The Stop TB Strategy, which builds on the DOTS strategy developed by the World Health Organization (WHO) and the International Union Against TB and Lung Disease, has a critical role in reducing the worldwide burden of disease and thus in protecting children from infection and disease. The management of children with TB should be in line with the Stop TB Strategy, taking into consideration the particular epidemiology and clinical presentation of TB in children. These consensus guidelines were produced to help the National Tuberculosis Programmes on the management of tuberculosis in children.

Author: WHO
Publisher: World Health Organization
ISBN: 9241548908
Category : Medical
Languages : en
Pages : 38

View

Book Description
BACKGROUND: Latent tuberculosis infection (LTBI), defined as a state of persistent immune response to prior-acquired Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB, affects about one-third of the world's population. Approximately 10% of people with LTBI will develop active TB disease in their lifetime, with the majority developing it within the first five years after initial infection. Currently available treatments have an efficacy ranging from 60% to 90%. Systematic testing and treatment of LTBI in at-risk populations is a critical component of WHO's eight-point framework adapted from the End TB Strategy to target pre-elimination and, ultimately, elimination in low incidence countries. OVERVIEW: Recognizing the importance of expanding the response to LTBI, in 2014 WHO developed Guidelines on the Management of Latent Tuberculosis Infection. The guidelines are primarily targeted at high-income or upper middle-income countries with an estimated TB incidence rate of less than 100 per 100 000 population, because they are most likely to benefit from it due to their current TB epidemiology and resource availability. The overall objective of the guidelines is to provide public health approach guidance on evidence-based practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. Specific objectives include identifying and prioritizing at-risk population groups for targeted intervention of LTBI testing and treatment, including defining an algorithm, and recommending specific treatment options. The guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management based on available resources, epidemiology of TB including intensity of transmission, the health-care delivery system of the country, and other national and local determinants.